“CA Rudramurthy BV is bullish on Glenmark Pharma, recommending a buy based on a clear bottom formation and accumulation pattern, aligning with the broader pharma sector's breakout. He sets a near-term target of 2,550 and an eventual target of 2,800, with a stop loss at 2,200.”

CA Rudramurthy BV’s track record: 17 graded calls · 95% CI 26–69%